383 S. Colorow Drive
Salt Lake City
33 articles with Recursion Pharmaceuticals
Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases
Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster
Recursion Enters Into Global Licensing Agreement with Takeda to Develop TAK-733 in Hereditary Cancer Syndrome
Recursion , a digital biology company industrializing drug discovery, today announced it has entered into a global licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to gain rights to TAK-733, a clinical-stage MEK inhibitor, and develop it for the treatment of a hereditary cancer syndrome and related areas of oncology. “TAK-733 is a great example of the power of our approach to decode challenging
3/27/2020Pharma and life sciences companies from across the globe provide updates on their pipelines and business.
3/20/2020Companies strengthen their leadership teams and board with this week's Movers & Shakers.
Former CEO of Navire Pharma and CoA Therapeutics to lead digital biology company’s pharmaceutical business and clinical development, including its newly formed Development Corporation SALT LAKE CITY--( BUSINESS WIRE )-- Recursion , a digital biology company industrializing drug discovery, today announced the appointment of Shafique Virani, M.D., as its Chief Corporate Development Officer. In this role, Dr. Virani will serve as both Recursion’s Chief
High-tech biopharma company partnering with childcare leader, Bright Horizons, to ensure working parents have the support they need to achieve their family and career ambitions
More than 860 teams participated in the competition with the goal of developing machine learning methods that identify representations of biology from Recursion’s first-ever open-source dataset
8/23/2019Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments.
Former VP of Talent at Intuit relocates from San Francisco to Salt Lake City to uplevel Recursion’s commitment to creating an inclusive and progressive workplace
Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced the closing of a $121 million Series C financing.
6/21/2019Biotech and pharma companies strengthen their leadership teams and committees with new appointments.
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
Recursion Releases Open-Source Data from Largest Ever Dataset of Biological Images, Inviting Data Science Community to Develop New and Improved Machine Learning Algorithms for the Life Sciences Industry
Clinical-stage biotech offering unique access to cell biology images with the goal of driving more effective artificial intelligence methods in drug discovery and development
Life science and technology startups led by members of underrepresented communities will be encouraged to apply
It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods.
Recursion Announces Options Exercise by Takeda and Extension of AI-enabled Drug Discovery Collaboration
From collaboration to licensing options in less than 18 months
Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process
Follows the successful completion of milestones set in the initial Phase 1 grant for $223,000, awarded in 2016.
Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, has been awarded a 2018 Top Workplaces award by The Salt Lake Tribune.
Recursion announced the company has appointed Tina M. Larson as Chief Operating Officer.
Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation
Recursion announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1 clinical trial of REC-994 in the treatment of cerebral cavernous malformation (CCM).